News & Updates

Surveillance of favourable-risk patients with metastatic renal cell carcinoma (mRCC) using risk stratification based on the International mRCC Database Consortium (IMDC) and number of metastatic sites may be done following cytoreductive nephrectomy without initiating systemic therapy, suggests a recent study.

Patients with metastatic prostate cancer who report high financial toxicity tend to spend less on basic goods and leisure activity and use their savings to pay for care, according to the results of a cross-sectional study.

Maintenance therapy with niraparib appears to increase progression-free survival (PFS) in patients with advanced ovarian cancer, irrespective of postoperative residual disease or biomarker status, according to data from the phase III PRIME study.

In patients with lenalidomide-refractory multiple myeloma (MM), a single infusion of ciltacabtagene autoleucel (cilta-cel), a dual-binding BCMA*-directed chimeric antigen receptor (CAR) T-cell therapy, improved progression-free survival (PFS) compared with standard of care** (SoC), according to the phase III CARTITUDE-4 trial.

Administration of booster doses of mRNA-based vaccines provide protection against COVID-19 and its adverse outcomes in patients with cancer who are actively receiving treatment as well as in cancer survivors, as shown in a study from Singapore.